Cargando…

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats

AIMS/INTRODUCTION: Type 2 diabetes mellitus is a risk factor of acute kidney injury after myocardial infarction (MI), a form of cardiorenal syndrome. Recent clinical trials have shown that a sodium–glucose cotransporter 2 (SGLT2) inhibitor improved both cardiac and renal outcomes in patients with ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Yukishige, Kuno, Atsushi, Tanno, Masaya, Sato, Tatsuya, Ohno, Kouhei, Shibata, Satoru, Nakata, Kei, Sugawara, Hirohito, Abe, Koki, Igaki, Yusuke, Yano, Toshiyuki, Miki, Takayuki, Miura, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626958/ https://www.ncbi.nlm.nih.gov/pubmed/30663266 http://dx.doi.org/10.1111/jdi.13009

Ejemplares similares

Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes
por: Muratsubaki, Shingo, et al.
Publicado: (2017)

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
por: Mizuno, Masashi, et al.
Publicado: (2018)

Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2018)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Accelerated Recovery of Mitochondrial Membrane Potential by GSK-3β Inactivation Affords Cardiomyocytes Protection from Oxidant-Induced Necrosis
por: Sunaga, Daisuke, et al.
Publicado: (2014)

Reply to the comment of Hirota et al. on “Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes”
por: Sato, Tatsuya, et al.
Publicado: (2019)

Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus
por: Nakata, Kei, et al.
Publicado: (2017)

Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats
por: Murase, Hiromichi, et al.
Publicado: (2015)

Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
por: Miki, Takayuki, et al.
Publicado: (2014)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Role of ER Stress in Ventricular Contractile Dysfunction in Type 2 Diabetes
por: Takada, Akifumi, et al.
Publicado: (2012)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
por: Zheng, Cankun, et al.
Publicado: (2022)

Emerging beneficial roles of sirtuins in heart failure
por: Tanno, Masaya, et al.
Publicado: (2012)

Renal Assessment in Acute Cardiorenal Syndrome
por: Łagosz, Piotr, et al.
Publicado: (2023)

Adenosine monophosphate deaminase in the endoplasmic reticulum–mitochondria interface promotes mitochondrial Ca(2+) overload in type 2 diabetes rat hearts
por: Osanami, Arata, et al.
Publicado: (2023)

Cardiovascular and Renal Links along the Cardiorenal Continuum
por: García-Donaire, José A., et al.
Publicado: (2011)

Endoplasmic Reticulum Stress in Diabetic Hearts Abolishes Erythropoietin-Induced Myocardial Protection by Impairment of Phospho–Glycogen Synthase Kinase-3β–Mediated Suppression of Mitochondrial Permeability Transition
por: Miki, Takayuki, et al.
Publicado: (2009)

Downregulation of extramitochondrial BCKDH and its uncoupling from AMP deaminase in type 2 diabetic OLETF rat hearts
por: Ogawa, Toshifumi, et al.
Publicado: (2023)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Renal injury in cardiorenal syndrome type 1 is mediated by albumin
por: Funahashi, Yoshio, et al.
Publicado: (2022)

Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
por: Botana, Manuel, et al.
Publicado: (2022)

Beyond the Cardiorenal Syndrome: Pathophysiological Approaches and Biomarkers for Renal and Cardiac Crosstalk
por: Buliga-Finis, Oana Nicoleta, et al.
Publicado: (2022)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Value of Renal Histology in Predicting Cardiorenal Outcomes in Heart Transplant–listed Patients
por: Barua, Sumita, et al.
Publicado: (2022)

Tricuspid regurgitation, right ventricular function, and renal congestion: a cardiorenal triangle
por: Forado-Benatar, Ilana, et al.
Publicado: (2023)

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2
por: van der Hoek, Sjoukje, et al.
Publicado: (2021)

Utility of a Score for Predicting Glomerular Filtration Rate Overestimation in Patients with Cardiovascular and Renal Diseases and Their Risk Factors
por: Ishigo, Tomoyuki, et al.
Publicado: (2022)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
por: Fujita, Yugo, et al.
Publicado: (2022)

Importance of anemia in the chronic Cardiorenal syndrome: Effects on renal function after heart transplantation
por: Libório, Alexandre Braga, et al.
Publicado: (2012)

Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1
por: Prins, Kurt W., et al.
Publicado: (2015)

Characterization of the Oxidative Stress in Renal Ischemia/Reperfusion-Induced Cardiorenal Syndrome Type 3
por: Caio-Silva, Wellington, et al.
Publicado: (2020)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
por: Liang, Yin, et al.
Publicado: (2012)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2019)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e8ifl1kribsnnc79ac31n1ch5t